IDEXX Laboratories posted a robust Q3 2025, achieving double-digit growth in revenue, earnings, and operating income, driven by strong performance in CAG Diagnostics and significant placements of inVue Dx instruments.
Revenue reached $1.105 billion, driven by 13% reported growth.
EPS was $3.40, with adjusted EPS at $3.22.
Net income rose to $274.6 million.
Strong demand for IDEXX inVue Dx and VetLab consumables supported performance.
IDEXX raised its full-year 2025 revenue and EPS guidance, driven by strong recurring revenue and instrument placement performance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance